JP and APM are full-time employees of Wave Life Sciences, LTD. TAM received speaker honorariums from Abbvie and the International Parkinson and Movement Disorder Society consultancies from CHDI Foundation/CHDI Management, Sunovion, Valeo Pharma, Roche, nQ Medical and Merz advisory board from Abbvie, Biogen, Sunovion, Medtronic, and research funding from EU Joint Programme - Neurodegenerative Disease Research, uOBMRI, Roche, Ontario Research Fund, CIHR, MJFF, Parkinson Canada, PDF/PSG, LesLois Foundation, PSI Foundation, Parkinson Research Consortium and Brain Canada. PK is Chief Scientific Officer and co-founder of VectorY. BB is an employee of Novartis Pharmaceuticals. ECG and CS are employees and receive salaries from CHDI Management. Hoffmann La Roche Ltd, Annexon, PTC Therapeutics, Takeda Pharmaceuticals Ltd, Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc, Alphasights, Genentech, LoQus23 Therapeutics, Triplet Theraputics, Novartis, Atalanta, Spark Therapeutics, Horama, University College Irvine, and Guidepoint, outside the submitted work in addition, SJT has a patent Application number 2105484.6 on the FAN1-MLH1 interaction and structural analogs licensed to Adrestia Therapeutics. SJT received funding from the CHDI Foundation, the UK Dementia Research Institute that receives its funding from DRI Ltd., the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK, and the Wellcome Trust (ref.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |